Universal Diagnostics Stock

UDX is an in-vitro diagnostics company developing a platform of minimally-invasive, blood-based solutions for the early detection of cancer

Sign up today and learn more about Universal Diagnostics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Universal Diagnostics Stock

Universal Diagnostics S.L. (UDX) is a Spanish in-vitro diagnostics company developing a platform of minimally-invasive, blood-based solutions for detecting cancer early when treatment options are more plentiful and survival rates are still high. UDX believes that the best way to fight against cancer is by detecting it early. The UDX diagnostic platform is designed to detect various cancer types, e.g. colorectal, liver, pancreatic, lung, and gastric cancer via one simple blood test. The assays rely on a curated set of proprietary methylation marker panels; a simple blood sample collected as part of a routine check-up, can be processed at a reference laboratory or hospital using standard equipment and then uploaded to the UDX Cloud for final algorithmic analysis. UDX’s first marker panel is a colorectal cancer screening test. The test identifies individuals who need to be referred for colonoscopy. Colorectal cancer is the 3rd most frequent cancer and 2nd deadliest cancer worldwide. The challenge is that colorectal cancer is mostly detected in late stages, with significantly decreased survival rates (11% survival rate in stage IV vs. 85% survival rate in stage I). To develop the test and execute its R&D and operations, UDX partners with international research institutions, hospitals, universities, and biobanks around the globe.

Funding History

December 2013$300K
March 2015$1.0M
November 2015$1.2M
March 2017$1.3M
December 2018$8.7M
March 2019$1.9M
March 2020$4.2M
July 2020$4.0M
January 2021$14.0M
November 2023$64.2M


Founder and CTO

Marko Bitenc


Christian Hense

Executive President, Founder & CEO

Juan Martinez Barea


healthclubmanagement - Dec, 20 2023

Fighting for recognition | HCM editor's letter

therecursive - Dec, 20 2023

How AI is Shaping the Future of Genetics

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: